Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus TENOFOVIR DISOPROXIL FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus TENOFOVIR DISOPROXIL FUMARATE.
EMTRICITABINE vs TENOFOVIR DISOPROXIL FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Nucleotide reverse transcriptase inhibitor; tenofovir diphosphate competitively inhibits HIV-1 and HBV reverse transcriptase and incorporates into viral DNA causing chain termination.
200 mg orally once daily, typically in combination with other antiretroviral agents.
300 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life: ~17 hours in HIV-infected patients; prolonged to ~28 hours in renal impairment (CrCl <50 mL/min).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Renal: ~70-80% unchanged via glomerular filtration and active tubular secretion; minimal biliary/fecal (<1% as unchanged drug).
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."